Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SCYNEXIS INC

Get SEC filing alerts via email and in your feed for SCYNEXIS INC

SCYX

SCYNEXIS INC

About SCYNEXIS INC

Scynexis, Inc. develops innovative antifungal medicines, focusing on a proprietary platform of triterpenoid agents called fungerps. Its lead product, ibrexafungerp, is approved for vulvovaginal candidiasis and under development for systemic fungal infections. The company collaborates globally, leveraging licensing agreements and clinical trials to address resistant fungal pathogens, with a competitive edge in oral, broad-spectrum, fungicidal antifungals targeting unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SCYNEXIS INC

1
1
SCYNEXIS INC SCYNEXIS Reports Increased Losses and Operating Expenses in Quarterly Filing

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
SCYNEXIS INC SCYNEXIS Reports $20.6 Million Revenue Growth and Advances SCY-247 Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SCYNEXIS INC SCYNEXIS Reports $8.6 Million Net Loss in Q3 2025, Progresses Drug Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SCYNEXIS INC SCYNEXIS Reports Q2 2025 Financial Results with Improved Net Loss and License Revenue Growth

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SCYNEXIS INC SCYNEXIS Reports 81.3% Revenue Decline and $5.4 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SCYNEXIS INC SCYNEXIS Reports 97.3% Revenue Decline and $21.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SCYNEXIS INC SCYNEXIS Reports Significant Financial Challenges, Net Loss of $2.8M in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments